TCL was part of the trial team that recently secured a $475 million antitrust verdict against the makers of the brand drug Amitiza. The plaintiffs in that case—In re Amitiza Antirust Litig., No. 21-11057 (D. Mass.)—alleged that Amitiza’s manufacturer, Takeda Pharmaceuticals USA, effectively paid its competitors to withhold generic Amitiza from the market, which allowed Takeda to continue selling its own brand drug at inflated prices. After a five-week trial, the jury awarded the class $475 million, which is automatically tripled under the federal antitrust laws, resulting in $1.4 billion in relief for the class—one of the largest results ever achieved in a “pay for delay” case.